vs

Side-by-side financial comparison of IRIDEX CORP (IRIX) and Linde plc (LIN). Click either name above to swap in a different company.

IRIDEX CORP is the larger business by last-quarter revenue ($14.7M vs $8.8M, roughly 1.7× Linde plc). On growth, Linde plc posted the faster year-over-year revenue change (8.2% vs -69.7%). Over the past eight quarters, IRIDEX CORP's revenue compounded faster (11.9% CAGR vs -96.7%).

IRIDEX Corporation is a global medical technology company that designs, manufactures and distributes advanced laser-based medical devices, primarily serving the ophthalmology and aesthetic medicine sectors. It supplies products to healthcare providers, clinics and medical facilities across North America, Europe, Asia Pacific and other regions, delivering minimally invasive solutions for eye disease treatment and cosmetic procedures.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

IRIX vs LIN — Head-to-Head

Bigger by revenue
IRIX
IRIX
1.7× larger
IRIX
$14.7M
$8.8M
LIN
Growing faster (revenue YoY)
LIN
LIN
+78.0% gap
LIN
8.2%
-69.7%
IRIX
Faster 2-yr revenue CAGR
IRIX
IRIX
Annualised
IRIX
11.9%
-96.7%
LIN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
IRIX
IRIX
LIN
LIN
Revenue
$14.7M
$8.8M
Net Profit
Gross Margin
37.2%
48.5%
Operating Margin
27.8%
Net Margin
Revenue YoY
-69.7%
8.2%
Net Profit YoY
EPS (diluted)
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IRIX
IRIX
LIN
LIN
Q1 26
$8.8M
Q4 25
$14.7M
$8.8B
Q3 25
$12.5M
$8.6B
Q2 25
$13.6M
$8.5B
Q1 25
$11.9M
$8.1B
Q4 24
$12.7M
$8.3B
Q3 24
$11.6M
$8.4B
Q2 24
$12.6M
$8.3B
Net Profit
IRIX
IRIX
LIN
LIN
Q1 26
Q4 25
$1.5B
Q3 25
$-1.6M
$1.9B
Q2 25
$-994.0K
$1.8B
Q1 25
$-1.7M
$1.7B
Q4 24
$-834.0K
$1.7B
Q3 24
$-1.9M
$1.6B
Q2 24
$-2.7M
$1.7B
Gross Margin
IRIX
IRIX
LIN
LIN
Q1 26
48.5%
Q4 25
37.2%
Q3 25
32.1%
Q2 25
34.5%
Q1 25
42.5%
Q4 24
44.0%
Q3 24
37.3%
Q2 24
40.7%
Operating Margin
IRIX
IRIX
LIN
LIN
Q1 26
27.8%
Q4 25
23.0%
Q3 25
-11.3%
27.5%
Q2 25
-6.9%
27.7%
Q1 25
-1.7%
26.9%
Q4 24
-3.9%
27.4%
Q3 24
-16.1%
25.0%
Q2 24
-20.9%
26.4%
Net Margin
IRIX
IRIX
LIN
LIN
Q1 26
Q4 25
17.5%
Q3 25
-12.6%
22.4%
Q2 25
-7.3%
20.8%
Q1 25
-14.2%
20.6%
Q4 24
-6.6%
20.8%
Q3 24
-16.7%
18.5%
Q2 24
-21.2%
20.1%
EPS (diluted)
IRIX
IRIX
LIN
LIN
Q1 26
$3.98
Q4 25
$3.28
Q3 25
$-0.09
$4.09
Q2 25
$-0.06
$3.73
Q1 25
$-0.10
$3.51
Q4 24
$-0.05
$3.61
Q3 24
$-0.12
$3.22
Q2 24
$-0.16
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IRIX
IRIX
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$6.0M
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$40.1M
Total Assets
$29.2M
$86.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IRIX
IRIX
LIN
LIN
Q1 26
$4.0M
Q4 25
$6.0M
$5.1B
Q3 25
$5.6M
$4.5B
Q2 25
$6.8M
$4.8B
Q1 25
$7.2M
$5.3B
Q4 24
$2.4M
$4.8B
Q3 24
$3.9M
$5.2B
Q2 24
$4.1M
$4.6B
Total Debt
IRIX
IRIX
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$1.0M
$15.3B
Q3 24
$1.4M
$17.5B
Q2 24
$16.9B
Stockholders' Equity
IRIX
IRIX
LIN
LIN
Q1 26
$40.1M
Q4 25
$38.2B
Q3 25
$4.7M
$38.6B
Q2 25
$6.1M
$38.5B
Q1 25
$852.0K
$38.0B
Q4 24
$2.1M
$38.1B
Q3 24
$2.6M
$39.2B
Q2 24
$4.2M
$38.2B
Total Assets
IRIX
IRIX
LIN
LIN
Q1 26
$86.3M
Q4 25
$29.2M
$86.8B
Q3 25
$28.4M
$86.0B
Q2 25
$31.6M
$86.1B
Q1 25
$34.2M
$82.7B
Q4 24
$29.1M
$80.1B
Q3 24
$30.2M
$82.5B
Q2 24
$31.2M
$80.2B
Debt / Equity
IRIX
IRIX
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.48×
0.40×
Q3 24
0.53×
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IRIX
IRIX
LIN
LIN
Operating Cash FlowLast quarter
Free Cash FlowOCF − Capex
$898.0K
FCF MarginFCF / Revenue
10.2%
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IRIX
IRIX
LIN
LIN
Q1 26
Q4 25
$3.0B
Q3 25
$-1.2M
$2.9B
Q2 25
$-397.0K
$2.2B
Q1 25
$-1.1M
$2.2B
Q4 24
$-1.2M
$2.8B
Q3 24
$-3.1M
$2.7B
Q2 24
$-1.3M
$1.9B
Free Cash Flow
IRIX
IRIX
LIN
LIN
Q1 26
$898.0K
Q4 25
$1.6B
Q3 25
$-1.2M
$1.7B
Q2 25
$-410.0K
$954.0M
Q1 25
$-1.2M
$891.0M
Q4 24
$-1.2M
$1.6B
Q3 24
$-3.1M
$1.7B
Q2 24
$796.0M
FCF Margin
IRIX
IRIX
LIN
LIN
Q1 26
10.2%
Q4 25
17.9%
Q3 25
-9.4%
19.4%
Q2 25
-3.0%
11.2%
Q1 25
-9.8%
11.0%
Q4 24
-9.8%
18.8%
Q3 24
-26.5%
19.9%
Q2 24
9.6%
Capex Intensity
IRIX
IRIX
LIN
LIN
Q1 26
Q4 25
16.6%
Q3 25
0.1%
14.8%
Q2 25
0.1%
14.8%
Q1 25
0.1%
15.7%
Q4 24
0.1%
15.1%
Q3 24
0.0%
12.8%
Q2 24
0.0%
13.7%
Cash Conversion
IRIX
IRIX
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons